BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH conference

Data show six-fold increase in mobilization of AML cells from bone marrow; Treatment with BL-8040 as single agent led to 70% decrease in AML cells in bone marrow and 3.5-fold increase in AML cell apoptosis

Read More